Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient

Harry Ross Powers, Moshe Bachar, Natasha Marie Savage, Michael Peter Toscano, Paul M Dainer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) is a hemato-logical malignancy of myeloid progenitor cells that disrupt normal hematopoiesis. Current chemotherapy regimens result in complete remission in many cases; however, there exists no standard efficacious therapy for refractory acute myeloid leukemia. The hypomethylating agent, azacitidine, is effective in a limited number of such cases. We present a 57-year-old Filipino male with acute myeloid leukemia who was refractory to two induction chemotherapy regimens; however, he achieved complete remission after palliative therapy with azacitidine. We report this case to demonstrate the efficacy of azacitidine in refractory acute myeloid leukemia. Although the effectiveness of azacitidine in improving overall survival has been shown, this case demonstrates the effect on remission induction in high risk AML. Further studies are needed to delineate subsets of acute myeloid leukemia in which azacitidine will serve as effective therapy and to identify other targeted agents that may potentiate its effects.

Original languageEnglish (US)
Article number5516
Pages (from-to)58-60
Number of pages3
JournalHematology Reports
Volume6
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Azacitidine
Salvage Therapy
Acute Myeloid Leukemia
Myeloid Progenitor Cells
Remission Induction
Induction Chemotherapy
Hematopoiesis
Palliative Care
Drug Therapy
Survival
Therapeutics
Neoplasms

Keywords

  • Acute myeloblastic/monocyt-ic/refractory
  • Azacitidine
  • Leukemia
  • Salvage chemotherapy

ASJC Scopus subject areas

  • Hematology

Cite this

Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient. / Powers, Harry Ross; Bachar, Moshe; Savage, Natasha Marie; Toscano, Michael Peter; Dainer, Paul M.

In: Hematology Reports, Vol. 6, No. 3, 5516, 01.01.2014, p. 58-60.

Research output: Contribution to journalArticle

Powers, Harry Ross ; Bachar, Moshe ; Savage, Natasha Marie ; Toscano, Michael Peter ; Dainer, Paul M. / Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient. In: Hematology Reports. 2014 ; Vol. 6, No. 3. pp. 58-60.
@article{6afce3c3e9834eb6b7c618a4a566711c,
title = "Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient",
abstract = "Acute myeloid leukemia (AML) is a hemato-logical malignancy of myeloid progenitor cells that disrupt normal hematopoiesis. Current chemotherapy regimens result in complete remission in many cases; however, there exists no standard efficacious therapy for refractory acute myeloid leukemia. The hypomethylating agent, azacitidine, is effective in a limited number of such cases. We present a 57-year-old Filipino male with acute myeloid leukemia who was refractory to two induction chemotherapy regimens; however, he achieved complete remission after palliative therapy with azacitidine. We report this case to demonstrate the efficacy of azacitidine in refractory acute myeloid leukemia. Although the effectiveness of azacitidine in improving overall survival has been shown, this case demonstrates the effect on remission induction in high risk AML. Further studies are needed to delineate subsets of acute myeloid leukemia in which azacitidine will serve as effective therapy and to identify other targeted agents that may potentiate its effects.",
keywords = "Acute myeloblastic/monocyt-ic/refractory, Azacitidine, Leukemia, Salvage chemotherapy",
author = "Powers, {Harry Ross} and Moshe Bachar and Savage, {Natasha Marie} and Toscano, {Michael Peter} and Dainer, {Paul M}",
year = "2014",
month = "1",
day = "1",
doi = "10.4081/hr.2014.5516",
language = "English (US)",
volume = "6",
pages = "58--60",
journal = "Hematology Reports",
issn = "2038-8322",
publisher = "PagePress",
number = "3",

}

TY - JOUR

T1 - Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient

AU - Powers, Harry Ross

AU - Bachar, Moshe

AU - Savage, Natasha Marie

AU - Toscano, Michael Peter

AU - Dainer, Paul M

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Acute myeloid leukemia (AML) is a hemato-logical malignancy of myeloid progenitor cells that disrupt normal hematopoiesis. Current chemotherapy regimens result in complete remission in many cases; however, there exists no standard efficacious therapy for refractory acute myeloid leukemia. The hypomethylating agent, azacitidine, is effective in a limited number of such cases. We present a 57-year-old Filipino male with acute myeloid leukemia who was refractory to two induction chemotherapy regimens; however, he achieved complete remission after palliative therapy with azacitidine. We report this case to demonstrate the efficacy of azacitidine in refractory acute myeloid leukemia. Although the effectiveness of azacitidine in improving overall survival has been shown, this case demonstrates the effect on remission induction in high risk AML. Further studies are needed to delineate subsets of acute myeloid leukemia in which azacitidine will serve as effective therapy and to identify other targeted agents that may potentiate its effects.

AB - Acute myeloid leukemia (AML) is a hemato-logical malignancy of myeloid progenitor cells that disrupt normal hematopoiesis. Current chemotherapy regimens result in complete remission in many cases; however, there exists no standard efficacious therapy for refractory acute myeloid leukemia. The hypomethylating agent, azacitidine, is effective in a limited number of such cases. We present a 57-year-old Filipino male with acute myeloid leukemia who was refractory to two induction chemotherapy regimens; however, he achieved complete remission after palliative therapy with azacitidine. We report this case to demonstrate the efficacy of azacitidine in refractory acute myeloid leukemia. Although the effectiveness of azacitidine in improving overall survival has been shown, this case demonstrates the effect on remission induction in high risk AML. Further studies are needed to delineate subsets of acute myeloid leukemia in which azacitidine will serve as effective therapy and to identify other targeted agents that may potentiate its effects.

KW - Acute myeloblastic/monocyt-ic/refractory

KW - Azacitidine

KW - Leukemia

KW - Salvage chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84907856833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907856833&partnerID=8YFLogxK

U2 - 10.4081/hr.2014.5516

DO - 10.4081/hr.2014.5516

M3 - Article

AN - SCOPUS:84907856833

VL - 6

SP - 58

EP - 60

JO - Hematology Reports

JF - Hematology Reports

SN - 2038-8322

IS - 3

M1 - 5516

ER -